{"id":759719,"date":"2021-10-07T18:27:00","date_gmt":"2021-10-07T18:27:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=062d176dfa08ae397e50ded4750ab682"},"modified":"2021-10-07T18:27:00","modified_gmt":"2021-10-07T18:27:00","slug":"cytodyn-to-present-at-emerging-growth-conference-on-october-13-followed-by-live-q-a","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/cytodyn-to-present-at-emerging-growth-conference-on-october-13-followed-by-live-q-a\/","title":{"rendered":"CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q\/A"},"content":{"rendered":"<p><![CDATA[VANCOUVER, Washington, Oct.  07, 2021  (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (\"CytoDyn\" or the \"Company\"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 30 minutes and 90 minutes will be dedicated to live questions and answers.]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71361],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/759719"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=759719"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/759719\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=759719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=759719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=759719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}